Want to see LTRN full AI Analyst Report?
Lantern Pharma (LTRN) Income Statement
Lantern Pharma Income Statement
Last quarter (Q2 2026), Lantern Pharma's total revenue was $0.00. In Q2, Lantern Pharma's net income was $-7.07M. See Lantern Pharma’s key income statements, including revenue, expenses, profit, and income.
| Income Statement | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 | |
| $ 0.00 | $ 0.00 | $ -174.84K | $ 0.00 | $ 0.00 | |
| $ 17.98M | $ 22.22M | $ 17.70M | $ 14.43B | $ 12.59M | |
| Depreciation and Amortization | $ 17.28K | $ 17.28K | $ 14.62K | $ 10.08K | $ 6.76K |
| $ -17.10M | $ -20.76M | $ -15.95M | $ -14.26B | $ -12.36M | |
| $ -17.98M | $ -22.22M | $ -17.88M | $ -14.43B | $ -12.59M | |
| $ 859.06K | $ 1.44M | $ 1.92M | $ 172.81M | $ 228.48K | |
| $ -17.12M | $ -20.78M | $ -15.96M | $ -14.26B | $ -12.36M | |
| $ -17.12M | $ -20.78M | $ -15.96M | $ -14.26B | $ -12.36M | |
| Per Share Metrics | |||||
| Basic EPS | $ -1.57 | $ -1930.92 | $ -1.47 | $ -1.31 | $ -1.13 |
| Diluted EPS | $ -1.57 | $ -1930.92 | $ -1.47 | $ -1.31 | $ -1.13 |
| Weighted Average Shares Outstanding | 10.90M | 10.76M | 10.84M | 10.85M | 10.90M |
| Weighted Average Shares Outstanding (Diluted) | 10.90M | 10.76M | 10.84M | 10.85M | 10.90M |
Currency in USD
